INCR:NASDAQIntercure Ltd. Analysis
Data as of 2026-04-10 - not real-time
$0.76
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The stock is trading below its 20‑day SMA (which lies under the 50‑day SMA) and remains under the 200‑day SMA, indicating a bearish technical backdrop. RSI sits near 44, suggesting neither overbought nor oversold conditions, while the MACD line has just crossed above its signal, offering a faint bullish hint. The price is squeezed between a support near $0.72 and resistance around $0.82, with volume trending downward, highlighting liquidity concerns.
Fundamentally, the company reports zero revenue to date but has released a preliminary 2025 revenue estimate of NIS 265 million and positive adjusted EBITDA, signaling potential upside. The balance sheet shows virtually no cash and a modest price‑to‑book of 0.1, while earnings per share remain negative. High 30‑day volatility (~34%) and a low beta (~0.47) point to price swings that are not strongly correlated with the market. Overall, the stock appears deeply discounted relative to its book value, yet it carries significant execution and regulatory risk.
Fundamentally, the company reports zero revenue to date but has released a preliminary 2025 revenue estimate of NIS 265 million and positive adjusted EBITDA, signaling potential upside. The balance sheet shows virtually no cash and a modest price‑to‑book of 0.1, while earnings per share remain negative. High 30‑day volatility (~34%) and a low beta (~0.47) point to price swings that are not strongly correlated with the market. Overall, the stock appears deeply discounted relative to its book value, yet it carries significant execution and regulatory risk.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- bearish technical trend with price below key moving averages
- proximity to support level and decreasing volume
- high short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- preliminary 2025 revenue guidance and positive adjusted EBITDA
- still negative earnings and cash flow
- moderate valuation relative to book
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- significant undervaluation on a price‑to‑book basis
- potential growth in the medical cannabis sector
- strategic alliance for cannabis therapeutics development
Key Metrics & Analysis
Financial Health
Revenue Growth3.40%
Profit Margin-29.17%
P/E Ratio-0.5
ROE-16.68%
ROA-7.74%
Debt/Equity41.49
P/B Ratio0.1
Free Cash Flow$-18398624
Industry P/E26.1
Technical Analysis
TrendBearish
RSI44.1
Support$0.72
Resistance$0.82
MA 20$0.76
MA 50$0.83
MA 200$1.27
MACDBullish
VolumeDecreasing
Fear & Greed Index87.32
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta0.47
Volatility33.80%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.